These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 31851035)

  • 1. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort.
    Martínez-Andrés JA; García-Carmona JA
    Int Clin Psychopharmacol; 2020 May; 35(3):163-169. PubMed ID: 31851035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
    Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
    Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
    Wang GH; Svensson M; Shao H; Vouri SM; Park H
    J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
    [No Abstract]   [Full Text] [Related]  

  • 5. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
    Basu A; Benson C; Alphs L
    J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
    Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
    Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort.
    Martínez-Andrés JA; García-Carmona JA
    Schizophr Res; 2019 Oct; 212():234-236. PubMed ID: 31421972
    [No Abstract]   [Full Text] [Related]  

  • 9. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
    Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
    Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
    DerSarkissian M; Lefebvre P; Joshi K; Brown B; Lafeuille MH; Bhak RH; Hellstern M; Bobbili P; Shiner B; El Khoury AC; Young-Xu Y
    Clin Ther; 2018 Sep; 40(9):1496-1508. PubMed ID: 30145029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.
    Emond B; El Khoury AC; Patel C; Pilon D; Morrison L; Zhdanava M; Lefebvre P; Tandon N; Joshi K
    Curr Med Res Opin; 2019 Mar; 35(3):407-416. PubMed ID: 30556739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
    Gutiérrez-Rojas L; Sánchez-Alonso S; García Dorado M; López Rengel PM
    CNS Drugs; 2022 May; 36(5):517-527. PubMed ID: 35460508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.
    Einarson TR; Bereza BG; Garcia Llinares I; González Martín Moro B; Tedouri F; Van Impe K
    J Med Econ; 2017 Oct; 20(10):1039-1047. PubMed ID: 28678566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
    Wallman P; Clark I; Taylor D
    J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
    Joshi K; Lafeuille MH; Brown B; Wynant W; Emond B; Lefebvre P; Tandon N
    Curr Med Res Opin; 2017 Oct; 33(10):1763-1772. PubMed ID: 28741387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
    Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
    [No Abstract]   [Full Text] [Related]  

  • 17. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.
    Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
    CNS Drugs; 2017 Apr; 31(4):273-288. PubMed ID: 28258365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
    Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
    Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
    J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
    Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
    J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.